13 results about "ERBB3" patented technology

The present invention relates to the field of therapeutic antibodies for use in the treatment of individuals with castration-resistant prostate cancer. More specifically, the present invention relates to the treatment of castration-resistant prostate cancer using a bispecific antibody comprising an antigen binding site that can bind to an extracellular portion of ERBB2 and an antigen binding site that can bind to an extracellular portion of ERBB3. In addition, the present invention relates to the treatment of castration resistant prostate cancer using an antibody comprising an antigen binding site that can bind to an ERBB3 extracellular portion. The invention also relates to the treatment of castration resistant prostate cancer using a combination of one of the antibodies and an androgen receptor axis-targeting agent.

The present invention relates to a humanised sequence binding the receptor tyrosine kinase ErbB3 / HER3 for the generation of anti-ErbB3 / HER3 antibodies in different formats, such as, for example, immunoglobulins, bispecific antibodies, in particular bispecific T-cell engagers, or antibody-drug conjugates (ADCs) or fusion immunoproteins, for the treatment of solid tumours depending on the expression of the ErbB3 receptor.

The present invention provides a composite drug for treating osimertinib-resistant non-small cell lung cancer, belonging to the field of biomedicine technology. Osimertinib combined with SR11302 inhibits the proliferation of drug-resistant cells and reduces the drug resistance of cells, so that the IC of cells to osimertinib is reduced. 50 The combined use of SR1302 and osimertinib decreased the expression of ERBB2, ERBB3, p-AKT, and p-ERK1 / 2; in mouse experiments, the combined use of osimertinib and SR11302 significantly inhibited tumor growth. This suggests that combined therapy may be an effective strategy to overcome osimertinib resistance and can provide more effective treatment options for NSCLC patients.

Disclosed is a pharmaceutical composition for preventing or treating a brain disease, containing as an active ingredient an ErbB3-binding protein 1 (EBP1) protein or a polynucleotide sequence encoding the EBP1 protein, wherein an EBP1 N84A / N204A protein, which is an EBP1 mutant in an asparagine endopeptidase (AEP)-uncleavable form, and a polynucleotide encoding the same can reduce amyloid beta production and enhance cognitive function in the early stages of Alzheimer's disease, and thus the composition can be advantageously used as a therapeutic agent for brain diseases including sporadic Alzheimer's disease.

The invention relates to the field of ErbB-2 and / or ErbB3 targeting agents, such as antibodies binding ErbB-2 and / or ErbB3. In particular it relates to the field of therapeutic (human) antibodies for the treatment of a ErbB-2 / ErbB-3 positive cell, tumor or cancer. More in particular it relates to treating malignant cells, tumors or cancers comprising high NRG1 expression levels.

The present invention relates to means and methods for treating castration-resistant prostate cancer. The present invention relates to the field of therapeutic antibodies for use in the treatment of individuals with castration-resistant prostate cancer. More specifically, the present invention relates to the treatment of castration-resistant prostate cancer using a bispecific antibody comprising an antigen binding site that can bind to an extracellular portion of ERBB2 and an antigen binding site that can bind to an extracellular portion of ERBB3. In addition, the present invention relates to the treatment of castration resistant prostate cancer using an antibody comprising an antigen binding site that can bind to an ERBB3 extracellular portion. The invention also relates to the treatment of castration resistant prostate cancer using a combination of one of the antibodies and an androgen receptor axis-targeting agent.

The present invention relates to a detection method for a plasma biomarker kit for major depressive disorder, which is used to detect plasma biomarkers for major depressive disorder. The present invention provides an application method for detecting one or more of the proteins ErbB3, MIF, NSE, and HGFR in plasma as a biomarker for major depressive disorder. The method of the present invention is used to assist in the diagnosis of major depressive disorder and improve the sensitivity and specificity of depression screening for the general population.

Provided herein are recombinant fusion proteins comprising an active fragment of neuregulin-1 (NRG-1) fused to a monospecific ErbB3 (HER3) monoclonal antibody (mAb), and methods of using same to treat cardiovascular disease.

The invention relates to the field of therapeutic antibodies for the treatment of a subject with castration-resistant prostate cancer. More in particular it relates to treating castration-resistant prostate cancer using a bispecific antibody that comprises an antigen binding site that can bind an extracellular part of ERBB2 and an antigen binding site that can bind an extracellular part of ERBB3. Also, it relates to treating castration-resistant prostate cancer using an antibody that comprises an antigen binding site that can bind an extracellular part of ERBB3. The invention also relates to treating castration-resistant prostate cancer using a combination of one of said antibodies and an androgen receptor axis-targeting agent.

This relates to anti-ERBB3 antibodies or their antigen-binding fragments and their pharmaceutical uses, particularly to fully human antibodies against the ERBB3 receptor or their antigen-binding fragments and their pharmaceutical uses. It also includes pharmaceutical compositions comprising fully human anti-ERBB3 antibodies or their antigen-binding fragments, and their use as anticancer drugs.

The invention relates to the field of ErbB-2 and / or ErbB3 targeting agents, such as antibodies binding ErbB-2 and / or ErbB3. In particular it relates to the field of therapeutic (human) antibodies for the treatment of a ErbB-2 / ErbB-3 positive cell, tumor or cancer. More in particular it relates to treating malignant cells, tumors or cancers comprising high NRG1 expression levels.

Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3 / HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3 / HER3.